Redensyl, a hair loss treatment that has been claimed to be 80% more effective than minoxidil, but users have not experienced any results from using it.
The user has been taking 0.5 finasteride for 10 months and wants to repeat blood tests, including estradiol. However, their doctor is reluctant to test estradiol, arguing it's typically low in men, and the user is considering seeking a second opinion.
0.5mg dutasteride reduces scalp DHT more than 1mg finasteride, leading to better hair regrowth results. Users report significant improvement with dutasteride compared to finasteride.
The user experienced concerning side effects like throat irritation, shortness of breath, chest pain, and testicle pain after using RU58841 for hair loss, despite also using finasteride and minoxidil. Other users shared mixed experiences, with one advising to stop using RU58841 due to similar side effects, while another reported significant hair loss reduction without side effects.
The user is experiencing a minoxidil shed after six months of use, noting a significant number of miniaturized hairs compared to mature ones, and has been on finasteride 0.5mg daily for two years with positive results. The user meticulously counts and categorizes shed hairs, sparking reactions ranging from amusement to concern over the level of obsession.
The conversation discusses using RU58841 mixed with topical minoxidil for hair loss, noting its chemical instability and storage challenges. A user shares their experience using RU58841 with ethanol and propylene glycol, mentioning no significant results yet.
Using a topical formula with 5% minoxidil and 0.01% retinoic acid is considered effective, as tretinoin can enhance minoxidil results and improve scalp health.
The user improved hair density from 45% to 70% using dutasteride and minoxidil, but still uses hair fibers for a fuller look. They added a topical mix of minoxidil, finasteride, and bimatoprost, but doubt further significant improvement.
A 26-year-old male is using a combination of clomiphene, minoxidil, tadalafil, bupropion, and lisdexamfetamine to address low testosterone, ED, depression, and focus issues. He seeks input on the safety and efficacy of this regimen, which also includes magnesium, zinc, and fish oil supplements.
Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.
PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.
The conversation discusses skepticism over the results of Pyrilutamide for hair regrowth, suggesting that results from rigorous trials are more trustworthy. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The user discovered they had been using fake minoxidil for almost two years, which stopped working, and switched to finasteride, which slowed hair loss. They recently started using real minoxidil and noticed a shedding phase, indicating it might be effective.
The conversation is about someone who had success using retinol with minoxidil for hair growth, but experienced shedding with Retin A (tretinoin). They are asking if others have tried retinol with minoxidil and what their results were.
A user experienced significant hair loss despite using Dutasteride and RU58841 for three years, questioning the effectiveness of these treatments. They are considering a scalp biopsy to explore other potential causes of hair loss.
A 42-year-old man shares his positive experience with minoxidil and finasteride for maintaining a healthy crown despite some flaking. Users discuss the effectiveness and appearance of his hair, with some suggesting Nizoral for flake management.
A user reported a significant increase in testosterone and estradiol levels after taking Finasteride for 5 months, with estradiol levels rising over 2000%. They plan to consult their doctor, suspecting a lab error, as they feel fine with no side effects.
A new hair loss treatment reportedly shows a 539% improvement in hair count, but skepticism remains due to unclear placebo results and potential minimal actual hair growth. Many users doubt its effectiveness and market viability, citing high costs and lack of visual proof.
The user is considering switching from topical finasteride to RU58841 or KX826 due to side effects like low libido and ED. They are also using oral minoxidil and considering low-dose saw palmetto to maintain their hairline.
A 24-year-old experienced significant hair regrowth using 1mg finasteride and 2.5mg oral minoxidil daily for four months, with minimal side effects. The results impressed many, and the user confirmed the treatments were prescribed by a doctor.
PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.
RU58841 worsened hair condition, causing thinning and unusual patterns. The user stopped using it two months ago but hasn't seen recovery, and there's speculation about androgen receptor upregulation.
The conversation is about sourcing RU58841 for hair loss treatment, with a focus on finding reputable sellers. The user plans to use 10mg/ml daily, split into two doses, prioritizing quality over price.
A user is seeing good results with RU58841 for hair loss, noting reduced shedding and thicker hair. They plan to use pumpkin seed oil as a solvent to avoid water content, which they believe reduces the effectiveness of anti-androgens.
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
2-Deoxy-D-Ribose is discussed as a potential hair loss treatment, but skepticism exists due to lack of human testing. The original poster uses a combination of topical Minoxidil, oral Finasteride, topical RU58841, and other treatments, reporting some hair regrowth but not significant results.
Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.